Reproductive Health Matters 2008;16(31 Supplement):162–172
PII: S 0 9 6 8 - 8 0 8 0 ( 0 8 ) 31 3 71 - 8
Mifepristone–Misoprostol and Misoprostol Alone:
Kristina Gemzell-Danielsson,a Sujata Lalitkumarb
a Professor, Department of Woman and Child Health, Division of Obstetrics and
Gynaecology, Karolinska Institutet, Karolinska University Hospital, Stockholm,Sweden. E-mail:
b Specialist in Obstetrics and Gynaecology, Department of Woman and Child Health,
Division of Obstetrics and Gynaecology, Karolinska Institutet, KarolinskaUniversity Hospital, Stockholm, Sweden
Abstract: Second trimester abortions constitute 10–15% of all induced abortions worldwide butare responsible for two-thirds of major abortion-related complications. During the last decade,medical methods for second trimester induced abortion have been considerably improved andbecome safe and more accessible. Today, in most cases, safe and efficient medical abortion servicescan be offered or improved by minor changes in existing health care facilities. Second trimestermedical abortion can be provided by a nurse–midwife with the back-up of a gynaecologist. Becauseof the potential for heavy vaginal bleeding and serious complications, it is advisable that secondtrimester terminations take place in a health care facility where blood transfusion and emergencysurgery (including laparotomy) are available. This article provides basic information on regimensrecommended for second trimester medical abortion. The combination of mifepristone andmisoprostol is now an established and highly effective method for second trimester abortion. Wheremifepristone is not available or affordable, misoprostol alone has also been shown to be effective,although a higher total dose is needed and efficacy is lower than for the combined regimen. Therefore, whenever possible, the combined regimen should be used. Efforts should be made toreduce unnecessary surgical evacuation of the uterus after expulsion of the fetus. Future studiesshould focus on improving pain management, the treatment of women with failed medical abortionafter 24 hours, and the safety of medical abortion regimens in women with a previous caesareansection or uterine scar. A2008 Reproductive Health Matters. All rights reserved.
Keywords: medical abortion, second trimester abortion, mifepristone, misoprostol, mid-level providers
ALTHOUGH the majority of abortions are siblefortwo-thirdsofallmajorabortion-related
performed in the first trimester, there is
complications. Medical abortion, the termination
still a need for second trimester abortion
of pregnancy through the use of a drug or a com-
because of delayed diagnosis of fetal anomalies,
bination of drugs, has the potential to reduce
logistic and financial difficulties in obtaining abor-
complications and to expand access to abortion
tion services, and failure to recognise an undesired
provided not only by specially trained clinicians
pregnancy in the first trimester, which all con-
but also by other health care providers who may
tribute to the continuing need for late abortion
or may not have training in surgical methods
Second trimester abortions constitute 10–15%
of abortion. Today, in most cases, safe and effi-
of all induced abortions worldwide but are respon-
cient medical abortion services can be offered or
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
improved by minor changes in existing health
question because of the disproportionate amount
care facilities. This article aims to provide basic
of abortion-related morbidity and mortality with
second trimester terminations, especially with
second trimester medical abortion and best prac-
tion (D&E) is the standard method of second tri-mester surgical abortion in many parts of theworld. In the United States, in 2000, D&E was
used for 99% of abortions between 13–15 weeks,
Different surgical and medical methods of abor-
95% between 16–20 weeks and 85% at 21 weeks
tion have been used since ancient times. Sur-
or laterIn England and Wales, D&E has also
gical abortion is one of the oldest and most
been the main method of second trimester abor-
commonly practised techniques in many parts of
tion; however, medical abortion is more common
the world. A matter of great concern in the past
than in the US and is increasingly being used. In
was that there were no safe drugs for inducing
contrast, medical abortion is the standard method
an abortion. Women have used various herbs,
for second trimester abortion in the Scandinavian
salts, douches and purgatives, all with question-
and Nordic countries since the introduction of
able success to achieve pregnancy termination.
the combined mifepristone–prostaglandin regi-
Among the methods listed as outdated by WHO,
men. In many other European countries, second
but still commonly used in several developing
trimester abortions due to fetal abnormalities
countries (e.g. India, China and until recently
are also performed using medical methods.
Mongolia), is intra- or extra-amniotic adminis-
There is a gradual increase in second trimester
tration of ethacryidine lactate (Rivanol), especially
abortion in some European countries because of
to terminate late second trimester pregnancies.
wide-scale introduction of antenatal screening
The drawbacks of older methods include long
programmes to detect fetal abnormalities such
duration of labour, hospitalisation for several days
as anencephaly and cardiovascular and skeletal
and the need for curettage. In recent years, effec-
malformations. In these cases, examination of the
tive medical abortion methods with low morbidity
fetus could provide valuable information, which
have emerged and are becoming more accessible.
medical abortion allows, to confirm the congen-
With the introduction of prostaglandins and later
ital anomaly, further evaluate the subsequent
prostaglandin analogues, the efficacy of medi-
risk of recurrence and provide information to
cal abortion could be improved, and the risk of
help in counselling of these patients.
complications and side effects reduced. Medicallyinduced abortion was further improved whenmifepristone became available in the 1980s
Who can provide second trimester abortion?
With mifepristone, the induction-to-abortion inter-
Specialised training and a sufficient workload to
val was shortened, and the dose of prostaglandin
maintain the skills, as well as special instruments,
analogues required (and thus side effects) was
are required to perform D&E safely according to
reduced. Today, medical abortion is the method of
the World Health Organization (WHO) and the
Royal College of Obstetricians & Gynaecologists
Medical abortion during early pregnancy was
first approved in France in 1988 (up to 49 days
safety and efficacy of D&E in experienced
of amenorrhoea) followed by approval in the
UK (1991) and Sweden (1992) (up to 63 days
to perform this procedure at an advanced gesta-
of amenorrhoea in both the countries). A few
tion. Furthermore, a report on the confidential
years later approval followed in these countries
inquires into maternal deaths in the UK ques-
for second trimester medical abortion. However,
tioned the appropriateness of D&E for second
it was only in 1999–2000 that both early first
trimester abortion when safe and effective
and second trimester medical abortion with
medical alternatives exist.In the Scandinavian
mifepristone and a prostaglandin analogue were
countries, the use of second trimester medical
approved in several other European countries.
abortion assures wide access to induced abortion
The optimal method of second trimester abor-
since it can be performed in all gynaecological
tion continues to be debated. This is an important
clinics. Furthermore, in these settings mid-level
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
providers with adequate training and back-up
The oral tablet is effective in different routes of
can provide the abortion care. Because of the
administration and the dose of prostaglandin
potential for heavy vaginal bleeding and serious
can be easily adjusted according to need. In
complications in a small number of women,
contrast to other prostaglandins, misoprostol has
however, it is advisable for second trimester ter-
limited effect in the bronchi or blood vessels.
minations to take place in health care facilities
Side effects are dose dependent, usually mild and
where gynaecologists, blood transfusion and
access to emergency surgery (including laparot-omy) are available.
Indications and usageAlthough in most countries mifepristone fol-
lowed by a prostaglandin analogue is approved
For abortion at 13–24 weeks of gestation, medi-
for medical termination of early first trimester
cal abortion with mifepristone followed by a
pregnancy (Mifepristone, Exelgyn, Paris, France),
prostaglandin (PG) analogue is an appropriate
mifepristone with repeated doses of a prosta-
method and has been shown to be safe and effec-
glandin analogue (most commonly misoprostol)
is also licensed and widely used for abortion of
misoprostol has synergistic effects and stimulates
later pregnancies. Studies carried out in many dif-
ferent countries provide evidence of the safety of
medical abortion up to 24 weeks of pregnancy
However, it should be noted that while the
dose of mifepristone does not change, the dose
of misoprostol needs to be modified according
Mifepristone is the only antiprogestin ap-
to gestational age. A higher total dose is often
proved for the induction of abortion. It is a 19-
needed in the late first trimester compared to the
norsteroid, which binds with high affinity to the
early first trimester. During the second trimester,
progesterone receptor, thus inhibiting the effect
due to increased sensitivity of the uterine mus-
of progesterone. Progesterone is a key hormone
cles to PGs, lower doses are sufficient. One needs
in maintaining pregnancy by keeping the uterus
to be very vigilant about hyperstimulation and
in a quiescent state. It prevents softening and
uterine rupture in cases with previous caesarean
dilatation of the cervix, reduces PG output from
section or any uterine scar in pregnancies beyond
the decidua and suppresses uterine contractions.
Thus, the blocking of progesterone receptors bymifepristone results in vascular damage, decidualnecrosis and bleeding,which leads to cervi-
cal softening, increased uterine sensitivity to PG
and conversion of the quiet pregnant uterus into
There are very few absolute contraindications
an organ of spontaneous activity with maximal
to medical abortion. When using a combination
of mifepristone and misoprostol they include:
Misoprostol is a synthetic PGE-1 analogue
which induces cervical ripening as well as strong
Previous allergic reaction to any of the drugs
uterine contractions and leads to expulsion of a
pregnancy. Prostaglandins play an important role
in the regulation of uterine contractility during
pregnancyThe receptors are present through-out the pregnancy; hence, PGs and PG analogues
are effective for termination of pregnancy. Miso-
prostol has been shown to have several advan-tages over other prostaglandins; it is cheap, stable
at room temperature and can be stored for a
long time. Misoprostol is equally or more effective
has pre-existing heart disease or cardiovascular
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
It should be remembered that complications and
prostol is dependent on the route of admin-
side effects with medical abortion increase with
istration. Vaginal misoprostol is more effective
increasing length of pregnancy. To reduce such
and has fewer side effects, but it may be less
complications abortion should be performed as
acceptable to some women. The sublingual route
early as possible without unnecessary delay; health
has therefore been investigated and shown to
care professionals should receive adequate train-
be convenient and acceptable although slightly
ing; and back-up services, including uterine evac-
uation and blood transfusion, should be available.
Interval between mifepristone and misopros-
tol: Maximal priming effect on the myometriumis achieved 36–48 hours after pre-treatment
with mifepristone. A shorter interval of 24 hours
resulted in a slightly longer induction-to-abortion
Mifepristone and misoprostol act synergistically
interval, a higher total dose of misoprostol used
in combination, and where both are available
and a higher rate of uterine curettage (pb0.001)
both should be used. Misoprostol alone should
Similarly, retrospective data comparing 24- and
be used in countries where mifepristone is not
48-hour intervals showed that when the interval
available. As with early medical abortion, the
was reduced to 24 hours, the induction-to abor-
goal has been to find a regimen combining the
tion interval was longer (9.8 hours vs. 7.5 hours)
lowest doses of both drugs that is highly effec-
(pb0.01)As both of these studies report sig-
tive and has the fewest side effects, and which
nificantly longer induction times, the 36–48 hour
administration interval may be preferable if prac-
For second trimester abortion (13–24 weeks of
gestation), medical abortion with mifepristone fol-
About 0.2–0.4% of women abort with mifep-
lowed by a PG analogue is an appropriate method
and has been shown to be safe and effective,according to WHO and the RCOG.It has been
Misoprostol-alone regimen: if mifepristone is
well proven that pre-treatment with mifepristone
24–48 h before PG administration increases the
Vaginal misoprostol 400 micrograms, every
success rate, shortens the induction-to-abortion
3 hours, to a maximum of 5 vaginal doses.
interval and reduces the amount of PGs requiredin the second trimester–
In countries where mifepristone is not avail-
Second trimester abortion in prior caesarean
able or affordable, gemeprost or misoprostol
section patients should be carried out with caution.
alone have been shown to be effective, although
Routine surgical evacuation of the uterus fol-
a higher total dose is needed and is less effec-
lowing medical abortion is not required.
Analgesics should be offered to all women
induction-to-abortion interval, 10–15 hours, is
longer than with the combined treatment with
Vaginal misoprostol or gemeprost can be admin-
mifepristone. Since a higher dose is required,
istered either by the woman herself or by a clini-
the abortion process may have more side effects,
cian, according to the preference of the woman.
such as nausea, vomiting, abdominal pain, feverand shivering.There is also a higher rate of
failed abortion and continuing live pregnancy.
With the misoprostol alone regimen, 80–90% of
Mifepristone 200 mg orally, followed 36–
48 hours later by misoprostol 800 micrograms
A meta-analysis of randomised trials compar-
vaginally and thereafter by repeated doses
ing gemeprost with misoprostol (using various
of 400 micrograms misoprostol orally, every
dosage regimens of misoprostol) showed that
3 hours, to a maximum of 4 oral doses.
vaginal misoprostol compared with gemeprost
was associated with a reduced need for narcotic
misoprostol has an abortion rate as high as 97%
analgesia and surgical evacuation of the uterus
and the median induction-to-abortion interval
When a regimen of 400 micrograms of vaginal
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
misoprostol every 3 hours was compared with
number of misoprostol doses, whereas it is less
1 mg of gemeprost every 3 hours, the induction-
in older, parous women and those at lower
to-abortion interval was significantly shorter in the
gestations.However, none of these factors is
vaginal misoprostol groupMany misoprostol-
sufficiently predictive to be useful in the man-
alone regimens have been reported in the literature
agement of individual cases. Non-steroidal anti-
with good results. Most of the trials were conducted
inflammatory drugs (NSAIDs) are a potential
in pregnancies of 13–22 weeks. For this gestational
first-line treatment. They inhibit the produc-
period, a regimen of 400 micrograms of vaginal
tion of endogenous PGs which are important
misoprostol every 3 hours up to 5 doses is rec-
messengers responsible for uterine contrac-
ommended, as it appears to be effective without
tions, cramps and pain sensation. NSAIDs do
not interfere with the action of misoprostol and/or mifepristone on inducing cervical ripening,
Mifepristone–gemeprost regimen: going out
uterine contractilityor the time to abortion
and expulsion of the products of conception.
The role of advance or prophylactic analgesia,
Mifepristone 200 mg orally, followed 24–
conscious sedation and para-cervical block and
48 hours later by gemeprost 1 mg vaginally
their effectiveness, as well as women’s satisfac-
every 6 hours to a maximum of five pessaries.
tion and acceptance, need further research.
in medical abortion and cervical priming untilmisoprostol became available.Vaginal geme-
prost-only regimens have an abortion rate of
Side effects, including nausea, vomiting and diar-
88–96.5% with a longer induction-to-abortion
rhoea, are characteristics of PG administration
interval compared to the combined regimen.
and are caused by PG’s stimulatory effect on the
With pre-treatment with mifepristone, the abor-
gastrointestinal tract. Diarrhoea is more common
tion rate in 24 hours was increased from 72%
in women using gemeprost, whereas fever is more
to 95the induction-to-abortion interval was
reduced from 15.7 to 6.6 hours and the PG dose
cations, such as uterine rupture, major haemor-
was also reduced without loss of clinical efficacy
rhage and cervical tear, are rare.Uterine
rupture cases are reported to occur with both
shown to be highly effective, gemeprost has sev-
gemeprost and misoprostol, with or without
eral disadvantages compared with misoprostol (i.e.
cost and the need for refrigeration limits its usage
uterine rupture in women without previous scar
in developing countries), which has led to miso-
is estimated to be 0.1–0.2% in the second tri-
prostol replacing gemeprost for all indications.
mester of pregnancy using mifepristone andgemeprMajor bleeding is usually asso-ciated with prolonged retention of the placenta.
Heavy bleeding requiring transfusion has been
adverse effects of medical abortIn routine
tion may occur with any induced abortion. About
clinical practice, analgesia should be offered to
3% of women required antibiotic treatment
all women. The perception of pain and request
because of suspected infections in a large series
for pain relief has wide individual and cultural
of over 1,000 women who had a second tri-
variations. Services should make a range of
oral and parenteral analgesics available to meetwomen’s needs.Pain is most likely to be feltin the first few hours after PG analogue admin-
istration. Studies have shown that analgesic
requirement and the perception of pain are sig-
When medical abortion is chosen, in many set-
nificantly higher in women of younger age and
tings, clinicians are legally required to ensure
those at a higher gestational age, with a longer
that the fetus is dead at the time of abortion.
induction-to-abortion interval and with a greater
According to the RCOG, a legal abortion must
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
not be allowed to result in a live birth, and at
abortion. It should only be undertaken if there is
terminations after 21 weeks, the method chosen
clinical evidence that the abortion is incomplete
should ensure that the fetus is not alive.This is
After the fetus is aborted, the placenta is usu-
especially important for late terminations (with
ally expelled within a short time. An injection
or without fetal malformation) if policy requires
of oxytocin may be given to help the expulsion
the provider to resuscitate if the fetus is born alive.
of the placenta. If the placenta is not delivered
Agents used for feticide are hypertonic saline,
within 1–2 hours, an infusion of 10 units oxyto-
1% lidocaine and potassium chloride or intra-
cin in 500 ml of normal saline at a rate of 20–
30 drops/min may be given to help the expulsion
21 weeks of pregnancy, the contractions induced
of the placenta or other uterotonic drugs accord-
ing to local guidelineAfter expulsion, theplacenta should be examined to see whether it iscomplete. If the placenta is incomplete, evacua-
tion of the uterus may be needed. If the placenta
Day-care abortion is recognised as a patient-
is not delivered after more than 1–2 hours obser-
centred and cost-effective form of service pro-
vation, or the woman starts bleeding excessively,
vision. In the era of older methods for inducing
evacuation of the uterus may be required.
second trimester abortion, a majority of women
After abortion, the woman should be observed
had to be inpatients for a couple of days to
in the hospital for at least 4 hours to monitor the
achieve abortion. The availability of abortion as
vital signs and the amount of vaginal bleeding. If
a day-care procedure can minimise disruption
there is heavy vaginal bleeding, a careful specu-
to the lives of women and their families. The
lum and pelvic examination should be performed
introduction of mifepristone treatment prior to
to exclude the possibility of lacerations of the
PG analogue has reduced induction-to-abortion
cervix. If there is no evidence of lacerations in the
intervals sufficiently such that many women
lower genital tract but the uterus is not contract-
(more than 75%) undergoing these procedures can
ing well and the bleeding persists, the uterine
be managed as day cases. With the regimen of a
cavity should be explored to see whether there
combination of mifepristone and vaginal miso-
are any retained products of conception.
prostol, as described above, the median induction-
In recent large case series of second trimester
abortion only 2.5–11% of women needed surgicalevacuation following medical abortion.Complete abortion is achieved with increasing
There are only a few studies reporting regimens
ing a routine evacuation, however, does not pro-
for women who do not abort within 24 hours.
tect against the need for hospital readmission for
According to some protocols, if abortion does
post-abortion bleeding and uterine curettage. A
not occur, mifepristone is given again, followed
more determined approach – using surgical evac-
uation only when needed – can be practised by
who fails to abort during the second day would
training staff in assessing placental completeness
get a third dose of mifepristone followed by
gemeprost 1 mg every 3 hours. There is still insuf-ficient consensus to set a guideline for the failedor delayed group of abortion patients, but it could
be argued that for women going on to a second
or third day, D&E would be a more appropriate
The caesarean section rate is generally increas-
approach.If a choice is available, the women
ing worldwide. Although many studies have
demonstrated the small risk of complications forvaginal birth at term after a prior caesarean sec-tion, experience with second trimester abortion
in women with prior uterine scar is limite
Routine surgical evacuation of the uterus is
Uterine rupture, haemorrhage and hysterotomy/
not required following second trimester medical
hysterectomy remain uncommon but are possible
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
complications of any second trimester termina-
tion method used. A literature review found that
Treatment with mifepristone and misoprostol
uterine rupture is associated with the use of high
typically involves two visits to the clinic by a
dose oxytocinAmong 23 women with a history
woman for pregnancy above nine weeks.It may
of prior caesarean section treated with the combi-
also include a follow-up visit a few weeks after
nation of mifepristone and gemeprost, one case of
asymptomatic uterine rupture was reported.Inaddition, there are case reports of uterine rupture
with the use of misoprostol in the scarred uterus
A single 200 mg tablet of mifepristone is takenorally. The woman is advised to return after 36–
48 hours for day-care admission to complete theabortion procedure with misoprostol. It is very
seldom that women abort with mifepristone
Both counselling and abortion should be pro-
(0.2–0.4% of cases), but the woman should be
vided without undue delay. Women should be
informed that this may occur. She should also be
free to choose to be counselled alone or with a
informed regarding expected effects of the drugs
partner, parent or friend. Ideally, pre-abortion
and possible side effects. In case of significant
counselling should also include contraceptive
bleeding and/or contractions the woman should
counselling and provision, making it possible to
begin the chosen method of contraception imme-diately after the abortion.
Second visitDuring the second visit the woman is admitted
to the clinic for misoprostol administration. An
In most cases, pregnancy is confirmed and its
initial dose of 800 micrograms vaginally fol-
length estimated on the basis of the woman’s his-
lowed by 400 micrograms orally every 3 hours,
tory and physical examination. Ultrasound exami-
to a maximum of 4 oral doses, is administered.
nation is not necessary in the majority of women,
Appropriate pain relief should be given during
although commonly used. It may be helpful to
the abortion. Abortion may take place after any
use ultrasound to diagnose pathologies or a non-
of the doses of misoprostol. After expulsion, the
placenta should be examined to see whether it iscomplete. If the placenta is incomplete, evacua-
Clinical assessment and laboratory investigations
A clinical history should be obtained to identify
The woman is kept under observation for at
contraindications and risk factors for compli-
least 4 hours after the expulsion to monitor the
cations. History of a patient should include per-
vital signs and the amount of vaginal bleeding.
sonal and family history of relevant diseases;
At discharge from the clinic, women should be
current use of any medications, allergies; obstetric
informed regarding expected effects and possi-
and gynaecological history; any bleeding tenden-
cies; and history of sexual transmitted infections.
From 15 weeks of pregnancy onwards, lacta-
Social history should include a risk assessment for
tion inhibition medication should be given.
sexually transmitted diseases, taking into accountlocal prevalence rates. Any genital infection shouldbe excluded or treatment started prior to the abor-
tion. The clinician must be alert to the possibil-
ity of violence or coercion in the context of the
start bleeding after the administration of miso-
prostol. Usually the amount of bleeding is not
Vital signs like pulse, blood pressure and
excessive. The cramps are due to uterine contrac-
temperature should be recorded at baseline and
tions, which are needed to abort the pregnancy.
during treatment. Haemoglobin level, blood
Appropriate information and pain medication
group and Rhesus (Rh) typing should be deter-
allow the woman to relax, which reduces dis-
mined. Rh-negative women should receive anti-
comfort. NSAIDs for pain relief can be given
together with misoprostol. Some women may
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
require narcotic analgesics or a para-cervical block
with regard to evaluation of the fetus and
placenta in cases of fetal malformation. This
would help in future research to develop better
emetics. Fever and chills are fairly common
ways to deal with complicated pregnancies.
after administration of misoprostol. These do not
Further studies are also needed on the treat-
indicate that the woman has an infection. Anti-
ment of women with failed medical abortion
pyretics may be given if necessary. These side
after 24 hours. There is also a need to further
effects usually subside or resolve 24 hours after
reduce unnecessary surgical evacuation of the
uterus after expulsion of the fetus and forguidelines on regimens to help the expulsionof the placenta. More studies are also needed
to evaluate the optimal combination of mife-
Future studies should focus on improving pain
pristone and misoprostol in women with prior
management. Medical abortion is advantageous
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
45. Wong KS, Ngai CS, Yeo EL, et al.
67. Bhide A, Sairam S, Hollis B, et al.
51. Bartley J, Brown A, Elton R, et al.
K Gemzell-Danielsson, S Lalitkumar / Reproductive Health Matters 2008;16(31 Supplement):162–172
Les avortements du deuxie`me trimestre repre´sentent
Los abortos de segundo trimestre constituyen
de 10 a` 15% des interruptions de grossesse
del 10 al 15% de todos los abortos inducidos
dans le monde, mais ils sont responsables des
mundialmente pero son responsables de dos
deux tiers des plus graves complications lie´es
terceras partes de las complicaciones ma´s graves
a` l’avortement. Ces dix dernie`res anne´es, les
relacionadas con el aborto. Durante la u´ltima
me´thodes me´dicamenteuses d’avortement du
de´cada, los me´todos me´dicos para el aborto
deuxie`me trimestre se sont sensiblement ame´liore´es
inducido en el segundo trimestre han mejorado
et sont devenues plus suˆres et plus accessibles.
considerablemente y son seguros y ma´s accesibles.
Aujourd’hui, dans la plupart des cas, des services
Hoy, en la mayorı´a de los casos, es posible
d’avortement me´dicamenteux suˆrs et efficaces
ofrecer o mejorar servicios seguros y eficientes
peuvent eˆtre propose´s ou n’exigent que quelques
de aborto con medicamentos haciendo pequen˜os
changements dans les e´tablissements sanitaires
cambios a los establecimientos de salud. El
existants. L’avortement me´dicamenteux du deuxie`me
aborto con medicamentos puede ser efectuado
trimestre peut eˆtre assure´ par une infirmie`re-sage-
en el segundo trimestre por una enfermera–partera
femme, avec l’appui d’un gyne´cologue ; en raison
profesional con el respaldo de un gineco´logo.
du risque d’abondants saignements vaginaux et
Dado el potencial de hemorragia vaginal y graves
de graves complications, il est souhaitable qu’il se
complicaciones, se aconseja que el aborto de
de´roule dans un centre de sante´ pouvant pratiquer
segundo trimestre se efectu´e en una unidad donde
une transfusion sanguine ou une intervention
sea posible realizar una transfusio´n sanguı´nea o
chirurgicale d’urgence (y compris une laparotomie).
cirugı´a de urgencia (incluida la laparotomı´a). En
Cet article donne des informations de base sur
este artı´culo se proporciona informacio´n ba´sica
les sche´mas recommande´s pour les avortements
sobre los regı´menes recomendados para el aborto
me´dicamenteux du deuxie`me trimestre. L’association
con medicamentos en el segundo trimestre. La
de mife´pristone et de misoprostol est maintenant
combinacio´n de mifepristona y misoprostol ahora
une me´thode confirme´e et tre`s efficace. Quand la
es un me´todo establecido y muy eficaz para el
mife´pristone n’est pas disponible ou trop one´reuse,
aborto de segundo trimestre. En los lugares donde
le misoprostol seul s’est aussi re´ve´le´ efficace,
no se dispone de mifepristona o donde no es
meˆme si la dose doit eˆtre augmente´e et si
asequible, se ha mostrado que misoprostol solo
l’efficacite´ est moindre. Par conse´quent, chaque
tambie´n es eficaz, aunque se necesita una dosis
fois que possible, il convient d’utiliser l’association
total ma´s alta y su eficacia es menor que la del
des deux me´dicaments. Il faut s’efforcer de re´duire
re´gimen combinado. Por tanto, siempre que sea
les e´vacuations chirurgicales inutiles de l’ute´rus
posible, se debe utilizar el re´gimen combinado. Se
apre`s l’expulsion du fKtus. Les e´tudes futures
deben realizar esfuerzos por reducir el nu´mero
devraient porter sur l’ame´lioration de la prise
de procedimientos innecesarios de evacuacio´n
en charge de la douleur, le traitement des e´checs
endouterina quiru´rgica despue´s de la expulsio´n del
de l’avortement me´dicamenteux dans les 24
feto. Futuros estudios deberı´an centrarse en mejorar
heures et la se´curite´ des sche´mas d’avortement
el manejo del dolor, el tratamiento de mujeres
me´dicamenteux chez les femmes ayant subi une
cuyo aborto con medicamentos fracase despue´s de
ce´sarienne ou pre´sentant une cicatrice ute´rine.
24 horas y la seguridad de los regı´menes de abortocon medicamentos en mujeres con antecedentesde cesa´reas o cicatrices uterinas.
Publikationen Originalarbeiten Blättner B, Kohlenberg-Müller K, Grewe A: Prävention von Adipositas bei Kindern und Jugendlichen: Neue Strategien sind erforderlich. Prävention 29, 42 – 46, Blättner B, Kohlenberg-Müller K, : Evaluation von zwei Adipositas-Programmen für Kinder und Jugendliche. Public Health Forum (51), 25, 2006 Blättner B, Kohlenberg-Müller K, Grewe A: Adiposi
Bryssel den 12.9.2012 COM(2012) 512 final EUROPAPARLAMENTETS OCH RÅDETS FÖRORDNING om ändring av förordning (EU) nr 1093/2010 om inrättande av en europeisk tillsynsmyndighet (Europeiska bankmyndigheten), när det gäller dess samspel med rådets förordning (EU) nr …/… om tilldelning av särskilda uppgifter till Europeiska centralbanken i fråga om politiken för tillsyn